百利天恒拟1亿元至2亿元回购股份，公司股价年内涨68.29%

Core Viewpoint - Baili Tianheng announced a share buyback plan with a total amount between 100 million and 200 million yuan, with a maximum buyback price of 546.00 yuan per share, which is 69.22% higher than the current price of 322.66 yuan, reflecting a strategy to stabilize stock prices [1] Group 1: Company Overview - Baili Tianheng Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, and was established on August 17, 2006, with its listing date on January 6, 2023 [1] - The company specializes in the research, production, and sales of pharmaceuticals, with its main business revenue composition being 99.57% recognized at a specific point in time and 0.43% recognized over a period [1] - The company belongs to the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, and is involved in concepts such as anti-cancer drugs and innovative medicines [1] Group 2: Financial Performance - As of September 30, 2025, Baili Tianheng reported a revenue of 2.066 billion yuan, a year-on-year decrease of 63.52%, and a net profit attributable to shareholders of -495 million yuan, a year-on-year decrease of 112.16% [2] - The number of shareholders increased by 25.08% to 5,979, while the average circulating shares per person decreased by 20.05% to 17,208 shares [2] Group 3: Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included notable funds such as China Europe Medical Health Mixed A, which held 3.7019 million shares, a decrease of 577,800 shares from the previous period [3] - Other significant shareholders included Hong Kong Central Clearing Limited and various ETFs, with notable reductions in holdings, indicating a shift in institutional investment [3]